Bayer Pays Arvinas $50m To Form Protein Degrader R&D Pact

The partnership gives the German major another potential source of drugs to treat cardiovascular, oncological and gynecological diseases.

Gears
Bayer adds another development partner to its R&D efforts • Source: Shutterstock

Bayer AG is moving into the development of protein degraders through a deal with Arvinas Inc. worth $50m upfront.

The potential for bifunctional small molecules to use cellular machinery to eliminate disease-causing proteins has attracted considerable interest, in large part because it offers a potential way to drug the estimated 80% of proteins that are beyond the reach of existing small molecules

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By 

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from Business

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.